Oncology Clinical Trials

  1. TH1902 is in early phase development in cancer patients with advanced solid tumors. The FDA has granted a Fast-Track development program for the investigation of TH1902 as a single agent, for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.
     
  2. TH1902-CTR-0001 (ClinicalTrials.gov Identifier: NCT04706962) is an open label first in human (FIH) study of TH1902 in solid cancers with 2 sequential parts:
     
    1. Part 1 (dose escalation): For patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard chemotherapy, surgery, radiation therapy, and for which no known effective therapies exist.  Patients will be dose-escalated until both the maximum tolerated dose (MTD) and the recommended dose (RD) for further development are determined and safety has been established.
       
    2. Part 2 (expansion): This part of the study will treat selected patient populations with advanced cancers that are known to express sortilin (SORT1) receptors, and which have relapsed or are refractory to standard chemotherapy, surgery, radiation therapy, and for which no known effective therapies exist.
       
  3. Part 1 of the study is currently open to recruitment only in the USA.  Once MTD, RD and safety are established, part 2 (expansion) will open in sites in the USA, UK, and Europe.
     
  4. The open sites are listed on gov and patients can contact those sites directly for more information about participation in the study.